A recent study reveals that people who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass far faster than those who stop conventional lifestyle plans.
Published data in a major health publication points out that while overweight people often shed substantial amounts of their total mass while on the medication, the weight comes back at an average rate of 0.8 kg per month after stopping.
"Individuals purchasing such drugs must be cognizant of the danger of rapid rebound weight gain when the medication ends," warns expert Dr. Susan Jebb.
That rate of recovery suggests a reversion to starting mass within about 18 months.
Analyzing Therapies
The study, which reviewed 37 of studies involving thousands of participants, compared the outcomes of the injectable medications with conventional dieting.
Scientists point out that people who shed pounds through lifestyle changes alone typically see a slower weight regain—perhaps 100 grams monthly—once they finish.
Understanding the Quick Rebound
Nutrition scientists suggest the mode of action of the drugs explains the heightened regain.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which controls appetite.
"Sustained high doses of the hormone levels several times higher than normal might result in the body to produce less of its endogenous GLP-1, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this hormone supplement results in hunger is uncontrolled, making binge eating much more probable."
A Lifelong Condition?
Health authorities suggest the injections for people with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
Many experts argue that, considering the high risk of relapse, the therapy is often ongoing.
This opinion is echoed by pharmaceutical companies, who state that the findings "emphasize the long-term nature of obesity," comparing it to managing conditions like high blood pressure.
User Accounts
Individuals who have discontinued the medication report a sudden return of hunger.
"It was like a switch that goes on and I was suddenly starving," described a patient.
The struggle is compounded if users have not developed lasting lifestyle or habit modifications during therapy.
Significant Use
Recent estimates suggest that millions of people in the UK have tried these injections in the past year, with demand continuing to grow.
- Use is greater among females compared to males.
- The middle-aged demographic shows the greatest level of interest.
- Many access the drugs through private healthcare rather than the NHS.
In conclusion, experts caution that while these medications are powerful tools for shedding pounds, they are not a permanent cure and lasting health benefits relies on combined behavioural management.
